Noven: Our Patch Problems Should Be Everyone’s Patch Problems
This article was originally published in The Pink Sheet Daily
Executive Summary
Potential generics for Daytrana need “real world” patch adhesion study, Noven argues, citing FDA worries about the firms’ own investigational product as support.